Endocrine Board Review 11th Edition (2019) Book

PURCHASERS OF EBR 11TH EDITION (2019) BOOK

EBR 11th Edition (2019) self-study book is a printed book mailed directly to purchasers or received directly on location. The EBR 11th Edition (2019) self-study book contains nearly 240 clinical case questions with answer rationales and references. The EBR 11th Edition (2019) self-study book is not available in electronic format.

 

    PURCHASERS OF EBR 11TH EDITION (2019) BUNDLE

    EBR Online 2019 sessions will be available approximately 3 weeks following the live conference that will be held September 17-18, 2019. EBR 11th Edition Bundle (2019) combines the self-study book and online presentations in a convenient and complementary learning experience. The bundle includes the EBR 11th Edition (2019) self-study book with nearly 240 clinical case questions as well as access to recorded presentations in EBR Online 2019  in a mock-exam format. 

    • EBR Online 2019 session will be available approximately 3 weeks following the live conference (held September 17-18, 2019)
    • EBR 11th Edition (2019) self-study book will be shipped directly to purchasers or received directly on location

     

    THIS COURSE PAGE IS FOR EBR 2019 BOOK

    Please follow the below links to claim CME credit and/or ABIM MOC points for the EBR Online 2019 sessions or the live EBR 2019 conference.

    EBR  Online  2019

    EBR 2019 Live Course

     

    EBR 11th EDITION BOOK INCLUDES

    • Printed self-study book
    • Nearly 240 case-based questions across endocrinology
    • Lab values provided in conventional and SI units
    • Up to 14.25 AMA PRA Category 1 Credits™ and 14.25 ABIM MOC Points

    Target Audience

    This activity will be of substantial interest to physicians and endocrine fellows preparing for the ABIM Endocrinology, Diabetes, & Metabolism Board Certification Exam or for those that simply want to stay up to date and improve their practice skills through knowledge assessment of diagnosis, treatment, and management of endocrine conditions.

    Learning Objectives

    Upon completion of this educational activity, participants will be able to (or better able to):

    • Enhanced medical knowledge and clinical skills across all major areas of endocrinology
    • Apply knowledge and skills in diagnosing, managing, and treating a wide spectrum of endocrine disorders
    • Successfully complete the board examination for certification or recertification in the subspecialty of endocrinology, diabetes, and metabolism

    Additional Information

    Target Audience: 
    Physician-in-practice
    Fellow
    Resident
    Clinical researcher
    Pharmacist
    Nurse/Nurse practitioner
    Physician assistant
    Allied health professional
    Other
    Competency Area: 
    Patient Care and Procedural Skills
    Medical Knowledge
    Topic Area: 
    Adrenal/HPA Axis
    Bone and Calciotropic Hormones
    Diabetes and Glucose Metabolism
    Lipid Disorders and Fatty Liver Diseases
    General Endocrinology
    Growth Disorders
    Hormones and Cancer
    Men’s Health
    Neuroendocrinology and Pituitary
    Obesity
    Thyroid/HPT Axis
    Women’s Health
    Level of Outcomes: 
    Level 1 (Participation)
    Level 2 (Satisfaction)
    Level 3A (Learning: Declarative Knowledge (Knows))
    Level 3B (Learning: Procedural Knowledge (Knows How))
    Level 4 (Learning: Competence (Shows How))
    Activity summary
    Available credit: 
    • 14.25 ABIM MOC
    • 14.25 AMA PRA Category 1 Credits
    • 14.25 CME Certificate of Participation
    Course opens: 
    09/05/2019
    Course expires: 
    12/31/2020
    Rating: 
    0

    EBR 11TH EDITION TABLE OF CONTENTS

                                                                                                QUESTIONS                     ANSWERS
    LABORATORY REFERENCE RANGES . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ....7

    COMMON ABBREVIATIONS USED IN EBR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..10

    ADRENAL BOARD REVIEW. . . . . . . . . . . . . . . . . . . . .. . . . . . . . . .12. . . . . . . . . . . . . . . . . . . .98
    Richard Auchus, MD, PhD

    CALCIUM & BONE BOARD REVIEW. . . . . . . . . . . . . .. . . . . . . . . .24. . . . . . . . . . . . . . . . . . . 116
    Carolyn B. Becker, MD

    DIABETES BOARD REVIEW (PART 1). . . . . . . . . . . . . . . . . . . . . .36. . . . . . . . . . . . . . . . . . . 142
    Serge A. Jabbour, MD

    DIABETES BOARD REVIEW (PART 2). . . . . . . . . . . . . . . . . . . . . .46. . . . . . . . . . . . . . . . . . . 163
    Michelle F. Magee, MD

    FEMALE REPRODUCTION BOARD REVIEW. . . . . . . . . . . . . . . . .56. . . . . . . . . . . . . . . .. . . 185
    Kathryn A. Martin, MD

    MALE REPRODUCTION BOARD REVIEW . . . . . . . . . . . . . . . . . . .62. . . . . . . . . . . . . . . . . ..196
    Frances J. Hayes, MB BCh, BAO

    OBESITY & LIPIDS BOARD REVIEW . . . . . . . . . . . . . . . . . . . . . . ..69. . . . . . . . . . . . . . . . . . . 210
    Andrea D. Coviello, MD

    PITUITARY BOARD REVIEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .78. . . . . . . . . . . . . . . . . . .235
    Laurence Katznelson, MD

    THYROID BOARD REVIEW. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...87. . . . . . . . . . . . . . . . . ..247
    Elizabeth N. Pearce, MD, MSc

    PROGRAM CHAIR

    Serge A. Jabbour, MD; Sidney Kimmel Medical College, Thomas Jefferson University

    FACULTY AUTHORS

    Richard J. Auchus, MD, PhD, University of Michigan Medical School
    Carolyn B. Becker, MD, Brigham and Women’s Hospital
    Andrea D. Coviello, MD, Duke University School of Medicine
    Frances J. Hayes, MB BCh, BAO, Massachusetts General Hospital
    Laurence Katznelson, MD, Stanford University
    Michelle F. Magee, MD, Georgetown University School of Medicine
    Kathryn A. Martin, MD, Massachusetts General Hospital
    Elizabeth N. Pearce, MD, MSc, Boston University Medical Center

    MEDICAL EDITOR

    Abbie L. Young, MS, CGC, ELS(D)

    STATEMENT OF INDEPENDENCE

    As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The content of this activity was developed under the supervision of the Endocrine Society’s Endocrine Board Review Committee.

    DISCLOSURE POLICY

    The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

    The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

    The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

    Richard J. Auchus, MD, PhD, has served as a consultant to Adrenas Therapeutics, Corcept Therapeutics, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Quest Diagnostics, Selenity Therapeutics, and Strongbridge Biopharma; and has conducted research for Neurocrine Biosciences, Novartis Pharmaceuticals, Spruce Biosciences, and Strongbridge Biopharma.
    Carolyn B. Becker, MD, receives royalties from UpToDate as a chapter author.
    Andrea D. Coviello, MD, has served as a consultant and speaker to Novo Nordisk; and has received research support from Allergan, Bristol-Myers Squibb, and Regeneron.
    Serge A. Jabbour, MD, has served as a consultant to AstraZeneca, Eli Lilly, and Janssen.
    Laurence Katznelson, MD, has received research support from Chiasma and Novartis; and has served as an advisory board member to Chiasma and Pfizer.
    Michelle F. Magee, MD, has had her institution receive research support from Lilly, Mytonomy, and Sanofi; has served as a speaker for PRIMED; and has served as a speaker and consultant to Mytonomy.
    Kathryn A. Martin, MD, serves as an editor for UpToDate

    The following faculty reported no relevant financial relationships: Frances J. Hayes, MB BCh, BAO, and Elizabeth N. Pearce, MD, MSc.

    The medical editor for this activity reported no relevant financial relationships: Abbie L. Young, MS, CGC, ELS(D).

    Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

    DISCLAIMER

    The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

    Use of professional judgment: 
    The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

    Drugs and dosages:
    When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

    POLICY ON UNLABELED/OFF-LABEL USE

    The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

    PRIVACY AND CONFIDENTIALITY STATEMENT

    The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

    Click "Start" to claim CME, MOC, and Certificate of Participation

    The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

    The Endocrine Society designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

     

    Review your Diplomate ABIM ID Number(s)

    In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:

    Provide your board-certification information in your educational profile.
    Your profile currently contains the following board ID numbers (must be logged in to view):

    My NameI am Certified by the ABIMMy ABIM NumberMy Date of Birth
    [current-user:profile-profile:field-first-name] [current-user:profile-profile:field-last-name]

    [current-user:profile-profile:field-cert-by-abim]

    [current-user:profile-profile:field-number-abim]

    [current-user:profile-profile:field-dob]

    *If your ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.

    Update Profile

    Available Credit

    • 14.25 ABIM MOC
    • 14.25 AMA PRA Category 1 Credits
    • 14.25 CME Certificate of Participation

    Accreditation Period

    Course opens: 
    09/05/2019
    Course expires: 
    12/31/2020

    Purchase is required. The EBR 11th Edition (2019) book is available as a standalone book or as part of a bundle with EBR Online 2019.